Mechanisms regulating PD-L1 expression in cancers and associated opportunities for novel small-molecule therapeutics
Antagonistic antibodies targeting the inhibitory immune-checkpoint receptor PD-1 or its
ligand PD-L1 are used to treat a wide range of cancer types and can substantially improve …
ligand PD-L1 are used to treat a wide range of cancer types and can substantially improve …
[HTML][HTML] Small molecules in targeted cancer therapy: advances, challenges, and future perspectives
L Zhong, Y Li, L Xiong, W Wang, M Wu… - Signal transduction and …, 2021 - nature.com
Due to the advantages in efficacy and safety compared with traditional chemotherapy drugs,
targeted therapeutic drugs have become mainstream cancer treatments. Since the first …
targeted therapeutic drugs have become mainstream cancer treatments. Since the first …
Programmed death ligand 1 signals in cancer cells
The paradigm of surface-expressed programmed death ligand 1 (PDL1) signalling to
immune cell programmed death 1 (PD1) to inhibit antitumour immunity has helped to …
immune cell programmed death 1 (PD1) to inhibit antitumour immunity has helped to …
Targeting cytokine and chemokine signaling pathways for cancer therapy
Cytokines are critical in regulating immune responses and cellular behavior, playing dual
roles in both normal physiology and the pathology of diseases such as cancer. These …
roles in both normal physiology and the pathology of diseases such as cancer. These …
Cancer stem cells in hepatocellular carcinoma—from origin to clinical implications
Hepatocellular carcinoma (HCC) is an aggressive disease with a poor clinical outcome. The
cancer stem cell (CSC) model states that tumour growth is powered by a subset of tumour …
cancer stem cell (CSC) model states that tumour growth is powered by a subset of tumour …
Regulatory mechanisms of immune checkpoints PD-L1 and CTLA-4 in cancer
The cytotoxic T-lymphocyte–associated antigen 4 (CTLA-4)/B7 and programmed death 1
(PD-1)/programmed cell death-ligand 1 (PD-L1) are two most representative immune …
(PD-1)/programmed cell death-ligand 1 (PD-L1) are two most representative immune …
Regulation of PD-L1 expression in the tumor microenvironment
M Yi, M Niu, L Xu, S Luo, K Wu - Journal of hematology & oncology, 2021 - Springer
Abstract Programmed death-ligand 1 (PD-L1) on cancer cells engages with programmed
cell death-1 (PD-1) on immune cells, contributing to cancer immune escape. For multiple …
cell death-1 (PD-1) on immune cells, contributing to cancer immune escape. For multiple …
Role of tumor microenvironment in cancer progression and therapeutic strategy
Q Wang, X Shao, Y Zhang, M Zhu, FXC Wang… - Cancer …, 2023 - Wiley Online Library
Cancer is now considered a tumor microenvironment (TME) disease, although it was
originally thought to be a cell and gene expression disorder. Over the past 20 years …
originally thought to be a cell and gene expression disorder. Over the past 20 years …
The hallmarks of cancer immune evasion
According to the widely accepted" three Es" model, the host immune system eliminates
malignant cell precursors and contains microscopic neoplasms in a dynamic equilibrium …
malignant cell precursors and contains microscopic neoplasms in a dynamic equilibrium …
[HTML][HTML] Mechanisms controlling PD-L1 expression in cancer
The engagement of programmed cell death protein 1 (PD-1; encoded by the PDCD1 gene)
receptor expressed on activated T cells and its ligand, programmed death-ligand 1 (PD-L1; …
receptor expressed on activated T cells and its ligand, programmed death-ligand 1 (PD-L1; …